NEW DELHI (Thursday, March 26, 2026) — A groundbreaking study published in the journal Science Advances has revealed that metformin, the world’s most widely prescribed diabetes medication, works by targeting a previously unknown pathway in the brain. For over 60 years, it was believed the drug acted solely on the liver and gut; however, this discovery identifies the brain as a “command center” for its glucose-lowering effects.
The Discovery: The Rap1-Hypothalamus Axis
Researchers at Baylor College of Medicine, led by Dr. Makoto Fukuda, identified a specific molecular “switch” in the brain that allows metformin to function at much lower doses than previously thought necessary.
- The Target Region: The study focused on the ventromedial hypothalamus (VMH), a part of the brain responsible for sensing glucose and regulating satiety.
- The Molecular Switch: A protein called Rap1 was found to be the key mediator. Metformin works by suppressing Rap1 activity in the VMH.
- Neural Activation: When Rap1 is inhibited, it activates a specific group of brain cells called SF1 neurons, which then send signals to the rest of the body to lower blood sugar.
[Image: Diagram of the human brain highlighting the Hypothalamus and the signaling pathway to the liver]
Key Evidence from the Study
The research team used genetically engineered models to prove that the brain is indispensable for metformin’s action.
| Experiment Type | Methodology | Result |
| Genetic Knockout | Mice were bred without the Rap1 protein in their brain’s VMH. | Metformin failed to lower blood sugar, even though other drugs like insulin still worked. |
| Direct Brain Injection | Tiny doses of metformin were injected directly into the brains of diabetic mice. | Blood sugar dropped significantly at doses thousands of times lower than typical oral doses. |
| Sensitivity Comparison | Compared the brain’s response to the liver and gut’s response. | The brain reacted to much lower concentrations, suggesting it is a primary site of action. |
Implications for the Future
This shift in understanding opens new therapeutic doors for treating type 2 diabetes and potentially other neurological conditions.
- Targeted Therapies: Future drugs could be designed to target the VMH Rap1 pathway directly, potentially reducing the side effects (like gastrointestinal distress) associated with high oral doses of metformin.
- Anti-Aging Potential: Metformin is already widely studied for its geroprotective (anti-aging) benefits. Dr. Fukuda’s team plans to investigate if this same Rap1 signaling is responsible for the drug’s ability to slow brain aging and improve longevity.
- Refined Prescribing: Doctors can now better understand why low doses of metformin are effective for some patients, as the brain-based mechanism is highly sensitive.
Sources
- ScienceDaily: “Metformin’s hidden brain pathway revealed after 60 years” (March 25, 2026).
- The Week: “Diabetes drug’s 60-year mystery solved: Scientists finally discovered how metformin works” (March 26, 2026).
- Science Advances: Lin et al., “Low-dose metformin requires brain Rap1 for its antidiabetic action” (Originally published 2025; Updated March 2026).
- Baylor College of Medicine News: “Researchers uncover a new player mediating metformin’s anti-diabetic action” (March 26, 2026).
Leave a Reply